Catalent breaks ground at US$112m drug product manufacturing facility

The Bloomington project in Indiana can create up to 200 new jobs and completion of both construction and recruitment are expected by the end of 2024

Pictured (l to r) at the ceremony are Jennifer Pearl, President, Bloomington Economic Development Corporation; Denis Johnson, General Manager, Catalent Bloomington; Barry Littlejohns, President, Biologics and Specialty Drug Delivery, Catalent; John Chiminski, Chair & CEO of Catalent; Eric Holcomb, Governor of Indiana; Mick Renneisen, Deputy Mayor, Bloomington; Mike Riley, VP/GM Catalent Biologics; and Kay Schmidt, SVP Technical Operations, Catalent

Catalent recently held a ground-breaking ceremony at its Bloomington (Indiana, US) site to mark the start of construction on a US$112m drug product manufacturing facility, which will increase fill/finish capacity in Bloomington by 79,000 square feet.

The facility will house a high-speed vial line utilising both ready-to-use components and bulk filling, a high-speed flexible syringe/cartridge line, a fully automated vial inspection machine and all associated services and support areas.